09-11-2015, 01:04 PM
Quote:It’s Friday. And according to the latest data for Gilead Sciences (GILD), hepatitis-C prescriptions continued to slow last week.
According to IMS, Harvoni prescriptions total fell 2% from the previous week to 7,333 during the week ended Sept. 4, while new prescriptions fell 3% to 2,672. Combined with Sovaldi, total hepatitis-C prescriptions fell 2% to 9,015, while new prescriptions declined 1% to 3,79.
RBC analyst Michael Yee estimates that U.S. hepatitis-C sales should come in at around $12.2 billion in 2015, just below the consensus for $12.7 billion.
From Barron's web site.
Not changing my theory and Ari's comments linked by Rapidacid just reinforced my thoughts.
=====
“While the dividend itself is merely a rearrangement of equity, over time it's more like owning an apple tree. The tree grows the apples back again and again and again, and the theoretical value of the tree doesn't change just because of when the apples are about to fall.” - earthtodan
“While the dividend itself is merely a rearrangement of equity, over time it's more like owning an apple tree. The tree grows the apples back again and again and again, and the theoretical value of the tree doesn't change just because of when the apples are about to fall.” - earthtodan